Proliferative activity of central neurocytoma: measurement of tumor volume doubling time, MIB-1 staining index and bromodeoxyuridine labeling index

J Neurooncol. 1997 Apr;32(2):103-9. doi: 10.1023/a:1005740205113.


Central neurocytoma is considered to be a benign intracranial neoplasm, but little is known about the biological behavior of this type of tumor. Proliferative activity of central neurocytoma was measured in 10 cases using MIB-1 staining for Ki-67 antigen. The MIB-1 staining value varied from < 0.1% to 5.6%, to indicating that some of these tumors have proliferative potential similar to that of anaplastic astrocytoma or malignant meningioma. The bromodeoxyuridine labeling index (BUdR LI, BrdU LI) was measured in 2 cases and the results correlated well with those of the MIB-1 analysis. Tumor volume doubling time (Td) measured in one case was 358 days which is similar to that of malignant meningioma. In one case, the MIB-1 value taken before and after 58 Gy of radiation treatment decreased markedly from 5.6% to 0.2%. The other 9 cases were also treated by radiation therapy (50-60 Gy) and no tumor recurrence was observed during follow-up periods ranging from 23 to 160 months. Another two patients with partially removed and 3 with subtotally removed tumors showing relatively high MIB-1 values might also have benefited from radiation therapy.

Publication types

  • Case Reports
  • Comparative Study

MeSH terms

  • Adult
  • Antibodies, Monoclonal
  • Brain Neoplasms / diagnostic imaging
  • Brain Neoplasms / pathology*
  • Brain Neoplasms / radiotherapy
  • Bromodeoxyuridine
  • Cell Division
  • Female
  • Humans
  • Ki-67 Antigen / immunology
  • Magnetic Resonance Imaging
  • Male
  • Neurocytoma / diagnostic imaging
  • Neurocytoma / pathology*
  • Neurocytoma / radiotherapy
  • Staining and Labeling
  • Tomography, X-Ray Computed


  • Antibodies, Monoclonal
  • Ki-67 Antigen
  • Bromodeoxyuridine